Objective: Osteopontin (OPN) is a multi-functional secreted glycoprotein that plays a crucial role in glucose metabolism and inflammatory process. Growing evidence suggests that there is a link between OPN and ovarian function. However, no such link has yet been found for OPN in polycystic ovary syndrome (PCOS). Our aim was to ascertain whether circulating OPN levels are altered in women with PCOS and to determine whether OPN levels differ between the follicular phase and mid-cycle of the menstrual cycle in eumenorrheic women. Design and methods: In total, 150 women with PCOS and 150 age-and BMI-matched controls without PCOS were recruited for this prospective observational study. OPN levels were measured using ELISA. Metabolic parameters were also determined. Results: Circulating OPN levels were significantly elevated in PCOS women compared with controls (69.12G31.59 ng/ml vs 42.66G21.28 ng/ml; P!0.001). OPN levels were significantly higher at mid-cycle than in the follicular phase in eumenorrheic women. OPN was positively correlated with BMI, homeostasis model assessment of insulin resistance (HOMA-IR), free testosterone, and high sensitivity C-reactive protein (hs-CRP). Multivariate logistic regression analyses revealed that the odds ratio (OR) for PCOS was 3.64 for patients in the highest quartile of OPN compared with those in the lowest quartile (ORZ3.64; 95% CIZ2.42-5.57; PZ0.011). Our findings indicate that BMI, HOMA-IR, hs-CRP, and free testosterone are independent factors influencing serum OPN levels and that OPN is an independent predictor for HOMA-IR. Conclusion: PCOS is associated with increased OPN levels.
Introduction
Polycystic ovary syndrome (PCOS) is a complex metabolic and reproductive disease. It is the most common endocrinopathy in women of reproductive age with a prevalence of 5-10%. PCOS is characterized by ovulatory dysfunction, polycystic ovaries, biochemical (elevated androgens), and/or clinical (hirsutism and/or acne) disease, the causes of PCOS remain to be identified. In affected women, the amount of adipose tissue is increased, especially in the central area. Adipose tissue is an active endocrine organ secreting many cytokines (i.e. adipokines), which play a crucial role in the regulation of metabolic and reproductive functions as well as in the inflammatory response. Adipose tissue dysfunction exists in PCOS; this situation causes alteration of secreted adipokines and inflammatory mediators. In addition, disturbed secretion of adipokines contributes to the development of PCOS and also to metabolic abnormalities in the disease (5, 6) .
Osteopontin (OPN) is a multi-functional secreted glycoprotein that plays a crucial role in a number of physiological and pathological events such as bone mineralization, atherosclerotic process, inflammation, insulin resistance, and malignant disorders. OPN is also a pro-inflammatory cytokine and an adhesion molecule which is expressed in various tissues including bone, bone marrow, vascular tissues, kidney, lungs, pancreas, ovary, and activated macrophages and T-lymphocytes (7, 8, 9, 10, 11, 12, 13) . It has been demonstrated that expression of OPN increases in adipose tissue in animal obesity model and obese subjects (14, 15) . OPN induces macrophagesmonocytes recruitment in adipose tissue; therefore, OPN is implicated in the pathogenesis of obesity-induced adipose tissue inflammation and associated insulin resistance (16, 17, 18) . Increased concentrations of OPN have been observed in diseases related to chronic low-grade inflammation and insulin resistance such as obesity, diabetes, diabetic nephropathy, and cardiovascular diseases (14, 19, 20, 21) .
There is also some evidence of a link between the OPN and ovarian function. Kuwabara et al. reported that OPN expression was stimulated in mouse ovaries by gonadotropin surge. They also observed that circulating OPN levels significantly increased following gonadotropin administration. They showed that OPN increases progesterone synthesis and expression of vascular endothelial growth factor (VEGF) in the early luteal phase (22) . In addition, it has been previously demonstrated that circulating levels of certain adipokines show variations during the menstrual cycle (23, 24) . Moreover, leptin surge (an adipokine) plays an active role in the onset of ovulation (23, 25) . Therefore, in this study, we aimed to investigate: i) whether circulating OPN levels were altered in women with PCOS; ii) whether OPN is correlated with metabolic disturbances; and iii) whether OPN levels differed between the follicular phase and mid-cycle of the same ovulatory cycle in eumenorrheic women.
Subjects and methods

Ethics statement
This study was approved by the Local Ethics Committee of the Bozyaka Training and Research Hospital. The subjects gave their oral and written informed consent before their inclusion in the study. The study adhered strictly to the Declaration of Helsinki Principles as revised in 2008.
Subjects and study design
The trial was designed as a prospective observational study and was conducted between January 2014 and December 2014 in the Department of Obstetrics and Gynecology of Merkezefendi State Hospital in Manisa, Turkey. We consecutively recruited 150 subjects with PCOS and 150 age-and BMI-matched subjects with normal menstrual cycles who presented to our clinic and met the inclusion and exclusion criteria. Forty healthy regularly menstruating women were randomly selected from the control group, and they followed mid-cycle (13-15 days) and mid-luteal phase (21-23 days) of the same menstrual cycle. We considered the cycle as ovulatory if a mid-cycle luteinizing hormone (LH) peak occurred and the mid-luteal serum progesterone exceeded a concentration of 10 ng/ml (26) . All progesterone levels in these women were higher than 10 ng/ml. Clinical and anthropometric variables were evaluated by a single investigator in all subjects. All the recruited women were Caucasian.
PCOS group
PCOS was diagnosed in this study based on the 2003 Rotterdam consensus criteria (27) . However, we were more rigorous in the selection of patients, and only those who met all three of the following criteria were recruited for the PCOS group (after excluding other causes of hyperandrogenism and ovulatory dysfunction): i) oligo and/or anovulation; ii) clinical and/or biochemical signs of hyperandrogenism -the Ferriman-Gallwey (FG) method was used to determine hirsutism (28) . Subjects were deemed hirsute if their FG score was R8. Biochemical hyperandrogenism was defined as an increase in the serum concentrations of free testosterone (normal values: 2.9-31.8 ng/dl) and/or total testosterone (normal values: 0.15-0.7 ng/ml), and/or a DHEAS (normal values: 10-248 mg/dl); and iii) typical ultrasonographic finding of polycystic ovaries (with one ovary being sufficient for diagnosis), defined as the presence of R12 follicles measuring 2-9 mm in diameter or an ovarian volume of O10 ml (without a cyst or dominant follicle in either ovary).
Control group
Control subjects were recruited from healthy women who visited the gynecology or endocrinology clinic for routine examination or from hospital workers and university students by means of an advertisement at the university. All volunteers for the control group had regular menstrual cycles, and they had no concomitant health problems or signs of hirsutism or acne or hyperandrogenism.
Exclusion criteria
The exclusion criteria adopted during subject selection were: i) other causes of irregular menstrual cycles and/or androgen excess (i.e. Cushing's syndrome; hyperprolactinemia; congenital adrenal hyperplasia; or other diseases of the adrenal gland, thyroid disorders, galactorrhea, breastfeeding, and pregnancy); ii) impaired glucose tolerance or type 1/2 diabetes; 3) hypertension, hyperlipidemia, active or chronic liver or renal failure, or congestive heart failure; iv) a history of coronary artery disease, gestational diabetes mellitus (GDM), or acute infection (within the preceding 14 days); v) presence of any chronic inflammatory and autoimmune disease; vi) known malignancy; vii) hormonal contraception and/or anti-androgen therapy (within the preceding 6 months); and viii) BMI !18.5 or R35 kg/m 2 , age !18
or O35 years. The use of medications for dyslipidemia, hypertension, hyperglycemia, insulin resistance, or obesity was an exclusion criterion for these studies. None of the subjects used tobacco or alcohol.
Anthropometric evaluation
Of the individuals included in the study, a detailed history was taken. Following general physical examination of the subjects, anthropometric measurements were performed (age, weight, height, and waist circumference). Height (cm) and weight (kg) were measured with the subject barefoot in light daily clothes. BMI was calculated using the formula weight (kg)/square meter of height (m 2 ).
Waist circumference (cm) was measured midway the lower rib margin and the iliac crest at the end of a gentle expiration. Blood pressure was measured in the sitting position after a rest period of at least 15 min. The average of three measurements was obtained.
Biochemical evaluation
Venous blood samples were collected from the antecubital veins of the subjects during the early follicular phase of menstrual bleeding (3rd-5th days) in the morning (between 0800-0900 h), after the onset of early spontaneous or progesterone-induced menses, following at least 12 h of fasting. Samples were separated by centrifugation for 15 min at 2000 g after clotting for 30 min at room temperature. The serum samples were subsequently stored in aliquots at K80 8C prior to the analysis of OPN. Furthermore, 40 women in the control group followed mid-cycle and in the luteal phase of the same menstrual cycle. Following at least 12-h fasting, blood was drawn in days 13-15 (ovulation) of the menstrual cycle to measure OPN and LH levels. Also, blood was drawn in days 21-23 (mid-luteal phase) of the menstrual cycle to measure progesterone levels. Fasting blood glucose (FBG), serum insulin, high sensitivity C-reactive protein (hs-CRP), total cholesterol, triglycerides, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), free testosterone, total testosterone, DHEAS, follicle-stimulating hormone (FSH), LH, estradiol (E 2 ), and OPN levels were measured.
FBG, serum hs-CRP, total cholesterol, total HDL-C, and triglyceride levels were determined using an autoanalyzer (Abbott Architect C 16000) with its dedicated kits (Abbott Diagnostics). LDL-C was calculated using the Friedewald equation: LDL-CZtotal cholesterolK(HDLCCtriglyceride/5). Serum insulin levels were measured by an auto-analyzer (Abbott Architect I2000) using chemiluminescent microparticle immunoassay (CMIA) with its dedicated kits (Abbott Diagnostics). Serum FSH, LH, E 2 , total testosterone, and DHEAS levels were measured by CMIA technique (Beckman Coulter, Inc., Brea, CA, USA). Serum free testosterone levels were measured using the RIA method (DSL 4900 Gamma Counter, Beckman Coulter, Inc., Fullerton, CA, USA). Insulin resistance was calculated for each participant using the homeostasis model assessment of insulin resistance (HOMA-IR)Zfasting insulin (mU/ml)!fasting glucose (mg/dl)/405 (29) . specificity for the detection of human OPN with no significant cross-reactivity or interference.
Statistical analysis
Power analysis " The power analysis was performed using G Power 3.0.10 for Windows. According to our pilot study results for circulating OPN levels, the required size of the study population was calculated to be 114 subjects/group (aZ0.05 and the study powerZ0.90).
Normal distribution of the data was tested using the Kolmogorov-Smirnov test. The skewness of the distribution required logarithmic transformation for statistical analysis of serum DHEAS. Continuous variables were presented as meanGS.D. Demographic and laboratory characteristics of the studied women with and without PCOS were compared using independent samples t-test (two-tailed). Differences in follicular phase and mid-cycle OPN levels in eumenorrheic women were analyzed by a paired t-test. Subjects were divided into two groups according to their BMI levels (BMI !25 and R25 kg/m 2 ).
We compared subjects according to their BMI in PCOS and control group using independent samples t-test (twotailed). We divided PCOS subjects into two groups according to the presence of insulin resistance (HOMA-IR O2.71 and %2.71). We compared serum OPN levels in the groups using independent samples t-test (two-tailed).
The relation of OPN with other demographic and laboratory characteristics was evaluated using Pearson's correlation analysis. Subjects were divided into four groups according to their OPN levels. To examine the association of OPN levels (quartiles) and the development of PCOS, odds ratio (OR) was calculated with multivariate logistic regression analysis. The model was adjusted for potential confounders (i.e. age, BMI, HOMA-IR, free testosterone, hs-CRP, and lipids). Model compatibility was analyzed using the Hosmer and Lemeshow test in all cases, and the analysis revealed that the models were compatible (PO0.05). To identify independent relationships between OPN levels and age, BMI, HOMA-IR, free testosterone, hs-CRP, and triglycerides multiple linear regression analyses were performed. To identify independent relationship between HOMA-IR and OPN, multiple linear regression analyses were performed (age, BMI, hs-CRP, lipids, and free testosterone were consecutively added in the analysis). In both multiple regression analyses, PCOS status was added for adjusting in models as a covariate. All independent variables in the multiple linear regression were tested for multicollinearity. If the variance inflation factor exceeded 2.5, the variable was considered to be collinear. Therefore, waist circumference, FBG, insulin, and total testosterone were not included in the models. All reported CI values are calculated at the 95% level. A two-sided P value !0.05 was considered statistically significant. All analyses were performed using the Statistical Package for the Social Sciences Software version 18.0 (SPSS, Inc.).
Results
Clinical and laboratory characteristics of the study population
The comparative demographic and laboratory parameters of the studied women with and without PCOS are given in Table 1 .
As subjects were matched for age and BMI, both parameters were similar in between the two groups (PO0.05).
Circulating OPN levels were significantly elevated in women with PCOS compared with controls (69.12G 31.59 ng/ml vs 42.66G21.28 ng/ml; P!0.001; Fig. 1A ). We divided PCOS patients into two groups as being insulin resistant or not (HOMA-IR O2.71 and %2.71) (30) . Out of 150 subjects, 98 were diagnosed as being insulin resistant. As shown in Fig. 1C , PCOS patients with insulin resistance had significantly elevated circulating OPN levels compared to those without insulin resistance (PZ0.014).
Comparison of follicular and mid-cycle serum OPN levels in healthy eumenorrheic women
Differences in follicular phase and mid-cycle Müllerian-inhibiting factor levels in the eumenorrheic women were analyzed by a paired t-test. Circulating OPN levels were higher at mid-cycle compared to the follicular phase (follicular phase: 40.82G18.99 ng/ml and mid-cycle: 44.90G20.53 ng/ml; PZ0.001). The results are shown as a box plot graph (Fig. 2) . Box plot for serum osteopontin levels in follicular and mid-cycle in eumenorrheic women.
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Correlation of OPN with clinical parameters
We next investigated the relationship between circulating OPN levels and various other parameters in women with PCOS. Correlation coefficients are shown in Table 2 . Circulating OPN levels were positively correlated with BMI, waist circumference, insulin, FBG, HOMA-IR, and hs-CRP in both groups. In addition, there was a positive correlation between OPN and free testosterone, triglycerides in only PCOS women. There was no significant correlation between OPN levels and age, blood pressure, and other lipids profile.
Multivariate binary logistic regression analysis
The independent association between PCOS and OPN levels (quartiles) was assessed by multivariate logistic regression analysis for the potential confounders including age, BMI, HOMA-IR, free testosterone, hs-CRP, and lipids (Fig. 3) .
Multivariate logistic regression analyses revealed that the OR for PCOS was 3.64 for patients in the highest quartile of OPN compared with those in the lowest quartile (ORZ3.64; 95% CIZ2.42-5.57; PZ0.011), after potential confounders. Odds of PCOS did not differ between subjects with the third (ORZ1.53; 95% CIZ0.89-2.63, PZ0.089), second (ORZ1.21; 95% CIZ0.71-2.06; PZ0.186), and the lowest quartile OPN.
Multivariate regression analysis
To verify independent associations between OPN and metabolic profile, multiple linear regression analyses were performed (Table 3) . This model explained 41.2% of the total variability in OPN concentration. Multiple linear regression analysis revealed that BMI, HOMA-IR, hs-CRP, and free testosterone independently predicted OPN levels.
To verify independent associations between OPN and HOMA-IR, multiple linear regression analysis was performed (Table 4) . In unadjusted analysis, OPN predicted degree of insulin resistance. To clarify the effects of OPN on HOMA-IR, age, BMI, hs-CRP, lipids, and free testosterone were consecutively added in the analysis as potential confounders. After adjustment for these parameters, OPN levels remained an independent predictor for HOMA-IR.
Discussion
Growing evidence suggests that OPN plays a role in the reproductive system of women. This is, to our knowledge, the first report describing the circulating OPN levels in PCOS patients. In the present study, we have found that circulating OPN levels were significantly higher in PCOS compared with controls, and also circulating OPN levels vary throughout the menstrual cycle in healthy eumenorrheic women, being higher at mid-cycle than in the Pearson's correlation analysis was used. r, Pearson's correlation coefficient. A P value of !0.05 was considered significant (*). Association of osteopontin (OPN) with PCOS in adjusted models. Multivariate adjusted OR for having PCOS according to follicular phase. Importantly, overweight/obese women also had significantly higher circulating OPN levels than lean women regardless of PCOS. PCOS patients with insulin resistance had significantly elevated circulating OPN levels compared with those without insulin resistance. Logistic regression analysis revealed that increased circulating OPN levels were significantly associated with high odds of having PCOS. Subjects with the highest quartile OPN levels showed a 3.64 times increased risk for having PCOS, compared to those in the lowest quartile after adjusting for potential confounders. In addition, multivariate regression analyses showed that BMI, HOMA-IR, hs-CRP, and free testosterone were independent factors influencing serum OPN levels. OPN is a multifunctional pro-inflammatory cytokine that is able to promote inflammation and insulin resistance in adipose tissues. Increased concentrations of OPN have been observed in diseases related to chronic low-grade inflammation and insulin resistance (16, 17, 18) . OPN levels were found to be elevated in type 2 diabetes mellitus compared with controls. OPN was positively correlated with FBG whereas it was inversely correlated with insulin sensitivity (20) . Gó mez-Ambrosi et al. reported that circulating OPN levels were elevated in overweight and obese subjects; furthermore, OPN concentration was correlated with body fat. In addition, they reported that OPN levels significantly decreased following weight loss (14) . PCOS is an inflammatory-based metabolic disease associated with insulin resistance (1, 2, 3) . In the present study, we found that circulating OPN levels were significantly elevated in women with PCOS compared with controls, and also we found a positive correlation between OPN and insulin resistance marker HOMA-IR. Our findings further indicated that OPN was an independent predictor of HOMA-IR. Moreover, insulinresistant PCOS subjects had elevated OPN levels compared with PCOS subjects without insulin resistance. Many women with PCOS have some degree of insulin resistance (5) . The pathogenic mechanisms involved in the increased insulin resistance associated with PCOS is still poorly understood, but accumulating evidence highlights the potential role of chronic low-grade inflammation as one of the main contributors (5). We can speculate that increased OPN levels may contribute to the development of insulin resistance in women with PCOS. On the other hand, contradictory results have been reported about OPN levels in GDM. In a study, OPN levels were found to be decreased in GDM compared with control and did not correlate with insulin sensitivity, whereas another study reported that OPN levels were not different between two groups (31, 32) .
Although the underlying pathophysiologic mechanisms have not yet been determined clearly, adipose tissue dysfunction exists in PCOS (5, 6) . Pro-inflammatory immune cell accumulation in adipose tissue is associated with the development of insulin resistance. OPN induces both macrophage recruitment in adipose tissue and secretion of cytokines. OPN plays a crucial role in the development of adipose tissue inflammation and insulin resistance (16, 17, 18, 33) . Increased expression of OPN has been reported in obese mice and obese humans (14, 15) . Adipose tissue dysfunction may also impact the pathophysiology of PCOS through its influence on metabolism and reproductive systems (6) . In the present study, circulating OPN levels were significantly elevated in women with PCOS, and also overweight/obese women had significantly higher circulating OPN levels than lean (22) recently reported that OPN might be involved in the regulation of follicular growth and ovulation. They showed that OPN expression increased in mouse ovarian granulosa cells in response to gonadotropin. They demonstrated that OPN increased progesterone synthesis and expression of angiogenic factor, VEGF. In addition, they observed circulating levels of OPN increased following gonadotropin administration. Consistent with this study, we found that circulating OPN levels vary throughout the menstrual cycle in healthy eumenorrheic women, being higher at mid-cycle than in the follicular phase. In light of these data, OPN might play a role in the ovulation. Taken together, increased circulating OPN levels in PCOS may implicate a possible other mechanism: there is a defect on OPN-mediated signaling pathway; therefore, secretion of OPN increases to overcome this problem in PCOS subjects.
There are some limitations to the current study. Although our sample size is relatively large, the crosssectional design of the study cannot prove causality. Another limitation the study has is the technique we used to evaluate insulin resistance. We used the less invasive HOMA-IR method, although it is inferior to the clamp technique. Lastly, we measured free testosterone levels using radioimmuno assay methods to determine androgen excess, although it is less reliable than free androgen index in women.
In conclusion, our results reveal elevated OPN levels in PCOS. However, it is not clear whether increased OPN levels are primary activators or they simply result from the disorder. In addition, OPN levels were significantly higher at mid-cycle than in the follicular phase in eumenorrheic women. More importantly, increased OPN levels were significantly associated with high odds of having PCOS. OPN may play a crucial role in the female reproductive system, including the development of PCOS and normal ovulation in humans. The physiological and pathological significance of our findings remains to be further elucidated.
